461 related articles for article (PubMed ID: 29475164)
21. The mode of action of thiazolidinediones.
Hauner H
Diabetes Metab Res Rev; 2002; 18 Suppl 2():S10-5. PubMed ID: 11921433
[TBL] [Abstract][Full Text] [Related]
22. Thiazolidinediones: a review of their mechanisms of insulin sensitization, therapeutic potential, clinical efficacy, and tolerability.
Vasudevan AR; Balasubramanyam A
Diabetes Technol Ther; 2004 Dec; 6(6):850-63. PubMed ID: 15684639
[TBL] [Abstract][Full Text] [Related]
23. PPAR agonists: multimodal drugs for the treatment of type-2 diabetes.
Gross B; Staels B
Best Pract Res Clin Endocrinol Metab; 2007 Dec; 21(4):687-710. PubMed ID: 18054742
[TBL] [Abstract][Full Text] [Related]
24. Minireview: Challenges and opportunities in development of PPAR agonists.
Wright MB; Bortolini M; Tadayyon M; Bopst M
Mol Endocrinol; 2014 Nov; 28(11):1756-68. PubMed ID: 25148456
[TBL] [Abstract][Full Text] [Related]
25. New approach in the treatment of T2DM and metabolic syndrome (focus on a novel insulin sensitizer).
Tjokroprawiro A
Acta Med Indones; 2006; 38(3):160-6. PubMed ID: 17119268
[TBL] [Abstract][Full Text] [Related]
26. Design, synthesis, and biological evaluation of novel pan agonists of FFA1, PPARγ and PPARδ.
Li Z; Zhou Z; Deng F; Li Y; Zhang D; Zhang L
Eur J Med Chem; 2018 Nov; 159():267-276. PubMed ID: 30296685
[TBL] [Abstract][Full Text] [Related]
27. Recent Updates on Free Fatty Acid Receptor 1 (GPR-40) Agonists for the Treatment of Type 2 Diabetes Mellitus.
Rani L; Grewal AS; Sharma N; Singh S
Mini Rev Med Chem; 2021; 21(4):426-470. PubMed ID: 33100202
[TBL] [Abstract][Full Text] [Related]
28. Effects of thiazolidinediones for early treatment of type 2 diabetes mellitus.
Kudzma DJ
Am J Manag Care; 2002 Oct; 8(16 Suppl):S472-82. PubMed ID: 12408410
[TBL] [Abstract][Full Text] [Related]
29. Pleiotropic effects of PPARγ agonist on hemostatic activation in type 2 diabetes mellitus.
Ferroni P; Della-Morte D; Pileggi A; Riondino S; Rundek T; Ricordi C; Guadagni F
Curr Vasc Pharmacol; 2013 May; 11(3):338-51. PubMed ID: 23650948
[TBL] [Abstract][Full Text] [Related]
30. The Potential Roles of Post-Translational Modifications of PPARγ in Treating Diabetes.
Ji X; Zhang W; Yin L; Shi Z; Luan J; Chen L; Liu L
Biomolecules; 2022 Dec; 12(12):. PubMed ID: 36551260
[TBL] [Abstract][Full Text] [Related]
31. PPAR agonists for the treatment of cardiovascular disease in patients with diabetes.
Wilding JP
Diabetes Obes Metab; 2012 Nov; 14(11):973-82. PubMed ID: 22443197
[TBL] [Abstract][Full Text] [Related]
32. Modulation of PPARgamma activity with pharmaceutical agents: treatment of insulin resistance and atherosclerosis.
Wang M; Tafuri S
J Cell Biochem; 2003 May; 89(1):38-47. PubMed ID: 12682906
[TBL] [Abstract][Full Text] [Related]
33. Balaglitazone: a second generation peroxisome proliferator-activated receptor (PPAR) gamma (γ) agonist.
Agrawal R; Jain P; Dikshit SN
Mini Rev Med Chem; 2012 Feb; 12(2):87-97. PubMed ID: 22372600
[TBL] [Abstract][Full Text] [Related]
34. Development of an In Vitro Screening Platform for the Identification of Partial PPARγ Agonists as a Source for Antidiabetic Lead Compounds.
Porskjær Christensen L; Bahij El-Houri R
Molecules; 2018 Sep; 23(10):. PubMed ID: 30248999
[TBL] [Abstract][Full Text] [Related]
35. Synthesis, docking, in vitro and in vivo antidiabetic activity of pyrazole-based 2,4-thiazolidinedione derivatives as PPAR-γ modulators.
Naim MJ; Alam O; Alam MJ; Shaquiquzzaman M; Alam MM; Naidu VGM
Arch Pharm (Weinheim); 2018 Apr; 351(3-4):e1700223. PubMed ID: 29400412
[TBL] [Abstract][Full Text] [Related]
36. [PPAR family and its relationship to metabolic syndrome].
Zhang XY; Chen LH; Guan YF
Sheng Li Ke Xue Jin Zhan; 2005 Jan; 36(1):6-12. PubMed ID: 15881336
[TBL] [Abstract][Full Text] [Related]
37. Safety issues and prospects for future generations of PPAR modulators.
Rubenstrunk A; Hanf R; Hum DW; Fruchart JC; Staels B
Biochim Biophys Acta; 2007 Aug; 1771(8):1065-81. PubMed ID: 17428730
[TBL] [Abstract][Full Text] [Related]
38. The Opportunities and Challenges of Peroxisome Proliferator-Activated Receptors Ligands in Clinical Drug Discovery and Development.
Hong F; Xu P; Zhai Y
Int J Mol Sci; 2018 Jul; 19(8):. PubMed ID: 30060458
[TBL] [Abstract][Full Text] [Related]
39. The role of PPARs in the microvascular dysfunction in diabetes.
Vinik A; Parson H; Ullal J
Vascul Pharmacol; 2006 Jul; 45(1):54-64. PubMed ID: 16784897
[TBL] [Abstract][Full Text] [Related]
40. Peroxisome proliferator activated receptor ligands for the treatment of insulin resistance.
Patsouris D; Müller M; Kersten S
Curr Opin Investig Drugs; 2004 Oct; 5(10):1045-50. PubMed ID: 15535425
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
